Document is current
Any future updates will be listed below
-
Authors
Stock, Sophia https://orcid.org/0000-0002-5072-5013
Benmebarek, Mohamed-Reda https://orcid.org/0000-0002-1201-7067
Kluever, Anna-Kristina https://orcid.org/0000-0001-6246-6082
Darowski, Diana https://orcid.org/0000-0002-8778-7920
Jost, Christian https://orcid.org/0000-0002-4169-5879
Stubenrauch, Kay-Gunnar
Benz, Joerg
Freimoser-Grundschober, Anne https://orcid.org/0000-0001-5715-3639
Moessner, Ekkehard
Umana, Pablo
Subklewe, Marion
Endres, Stefan https://orcid.org/0000-0002-4703-537X
Klein, Christian https://orcid.org/0000-0001-7594-7280
Kobold, Sebastian https://orcid.org/0000-0002-5612-4673
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04230265 at ClinicalTrials.govnct05199519 at ClinicalTrials.govDocuments that mention this clinical trial
P06.11 Immunotargeting of CD98hc for elimination of radioresistant head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-itoc7.90
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
https://doi.org/10.1136/jitc-2022-005054
Documents that mention this clinical trial
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
https://doi.org/10.1136/jitc-2022-005054
- License Information
